This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Leukemia	WEE1 tyrosine kinase (WEE1)	<p>Patient sample and cell culture studies suggest combining WEE1 inhibitors with cytarabine could help treat leukemia. In leukemia cell lines, cytarabine plus the WEE1 inhibitor MK-1775 increased apoptosis compared with either compound alone. Next steps include running a clinical trial of MK-1775 plus cytarabine in leukemia patients.</p> <p>Merck & Co. Inc.'s MK-1775 is in Phase II testing to treat solid tumors.</p> <p>Cytarabine is a generic chemotherapeutic used to treat hematological cancers.</p> <p>SciBX 5(6); doi:10.1038/scibx.2012.149 Published online Feb. 9, 2012</p>	Unpatented; licensing status not applicable	<p>Tibes, R. <i>et al. Blood</i>; published online Jan. 20, 2012; doi:10.1182/blood-2011-07-367557</p> <p>Contact: Raoul Tibes, Mayo Clinic, Scottsdale, Ariz. e-mail: tibes.raoul@mayo.edu</p>